1 company in City of St. Louis received one inspection in July

1 company in City of St. Louis received one inspection in July
Robert M. Califf, M.D. Commissioner of Food and Drugs - FDA — Official Website
0Comments

There was one company in the City of St. Louis, Missouri, that received an FDA inspection in July, according to reports from the U.S. Food and Drug Administration (FDA).

This is a 50% decrease from the number of companies inspected in the previous month, when two companies received two inspections.

The only company inspected was involved in the Food and Cosmetics sector.

The company was in line with FDA regulations, and doesn’t need to adjust its managing operations or regulatory/administrative actions.

The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.

The FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality, according to its website.

Companies Located in City of St. Louis and Their Inspection Results
Company Name Area of Business Inspection Date Result
T & R Enterprises USA, Inc. Food and Cosmetics 07/10/2024 No Action Indicated (NAI)


Related

Laura V. Swett, Chairman of Federal Energy Regulatory Commission (FERC)

Cheapest premium gas in St. Louis city reach $4.39 in week ending May 9

For the week ending May 9, the lowest reported price of premium gas in St. Louis city stood at $4.39 per gallon.

Laura V. Swett, Chairman of Federal Energy Regulatory Commission (FERC)

St. Louis city saw lowest price for regular gas at $3.69 in week ending Apr. 25

The lowest price for a gallon of regular gas in St. Louis city during the week ending Apr. 25 was $3.69, according to customer reports to GasBuddy.

Peter Mihalick, Public Policy VP for AMIA

Public Policy VP Mihalick scrutinizes 340B program for ‘shortchanging patients to increase profits,’ as 340B concerns grow in Missouri

Peter Mihalick of the American Medical Informatics Association warned that the 340B Drug Pricing Program may incentivize nonprofit hospitals to prioritize profits over patient savings, as scrutiny over the program continues to grow.

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from St. Louis Reporter.